Johnson & Johnson shares rose 0.54% to $260.21 in pre-market trading after falling 2.30% in the previous session, following two-year Phase 3 data for ICOTYDE (icotrokinra) in adults and adolescents aged 12 and older with at least moderate plaque psoriasis affecting high-impact sites. Results from the ICONIC-TOTAL study showed sustained skin clearance through Week 112 across the scalp, genitals, hands and feet. Overall clear or almost clear skin increased from 57% at Week 16 to 67% at Week 24 and 70% at Week 112. At Week 112, 60% of patients with scalp psoriasis achieved complete clearance, 89% of those with genital psoriasis achieved complete clearance and 63% of patients with hand or foot psoriasis achieved complete clearance. Mean improvement in nail psoriasis reached 71%. Johnson & Johnson reported no new safety signals, with findings consistent with ICOTYDE's established safety profile. ICOTYDE is a targeted oral peptide that blocks the IL-23 receptor and is approved in the U.S. for eligible adults and pediatric patients aged 12 and older weighing at least 40 kilograms.